TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01273246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 200U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U inactivated Enterovirus Type 71 Vaccine
Description: Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
Study: NCT03260621

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: stress CMR
Description: additional stress CMR to the established clinical diagnostics

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: stress CMR
Description: additional stress CMR to the established clinical diagnostics
Study: NCT03879824

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Secondary Radial Artery Access
Description: Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary Femoral Artery Access
Description: Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
Study: NCT02012751

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nevus doctor program
Description: The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
Study: NCT03132610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: andrographolide sulfonate
Description: Conventional Therapy+Xiyanping injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: andrographolide sulfonate simulation
Description: Conventional Therapy+Xiyanping injection simulation
Study: NCT02272569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARflo Glaucoma Implant
Description: Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
Study: NCT02888782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist Consultation
Study: NCT02190604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule- oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule- oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule- oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose
Study: NCT01307540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: low level light therapy, broad band light wavelengths.
Study: NCT02190604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QBW251
Description: Capsule - oral dose
Study: NCT03495102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study: NCT04402723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: In first 28-days-cycle, eligible subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination with Daunorubicin 60mg/m2/d, for first 3 days, and Cytarabine 100mg/m2/d, for first 7 days. If CR or CRi is observed, subjects will be given Donafenib 0.2/0.3g, bid, for first 14 days, combination Cytarabine 2g/m2/q12h, for first 3 days, in next 28-day-cycle.
Study: NCT02527785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Irinotecan, S-1(OIS)
Description: Treatment will be delivered every 2 weeks~1. oxaliplatin 65 mg/m2 iv on day 1~2. irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day po on day 1-7
Study: NCT03127176

Intervention type: OTHER
Intervention: Genome sequencing of fecal samples
Description: Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.

Intervention type: OTHER
Intervention: Genome sequencing of fecal samples
Description: Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.

Intervention type: OTHER
Intervention: Genome sequencing of fecal samples
Description: Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at -80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
Study: NCT02255994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UGYTEX
Description: Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No mesh.
Description: Patients in this arm had subvesical plication without reinforcement.
Study: NCT03742583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Square Knot
Description: Standard square knot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RHAP Knot
Description: Reversing half-hitch alternating post knot
Study: NCT04197180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Argon Plasma Coagulation
Description: Argon Plasma Coagulation after water injection for local ablation
Study: NCT04373005

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal (NP) swab
Description: A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.
Study: NCT04141423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tregopil
Description: Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tregopil
Description: Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tregopil
Description: Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tregopil
Description: Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
Study: NCT01307540

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: phototherapy
Description: low level light therapy, broad band light wavelengths.
Study: NCT02342899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)
Description: Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
Study: NCT02611908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibrutinib
Description: Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
Study: NCT02342899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)
Description: The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
Study: NCT01684319

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Formula milk free of cow's milk protein

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infant formula milk
Study: NCT05649761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1604 injection
Description: Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
Study: NCT01644240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8954
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-8954
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - saline
Description: Intravenous infusion
Study: NCT03058627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: FFR guided PCI
Study: NCT01390025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCN-032
Description: TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - 0.9% Sodium Chloride for Injection, USP
Study: NCT03690050

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode 577 nm subthreshold micropulse laser
Description: On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard threshold laser (532 nm laser)
Description: On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
Study: NCT02274883

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enriched Protein Fractions
Description: Enriched protein fractions

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Fractions
Description: Protein fractions
Study: NCT03379402

Intervention type: OTHER
Intervention: Specimens collection
Description: On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3.
Study: NCT03952182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Orthosis (LSO, TLSO)
Description: spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No orthosis
Description: no orthotic given for spinal fracture. These patient's will be given a bending restriction
Study: NCT03982992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab in combination with donor lymphocyte infusion
Description: Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
Study: NCT01549717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of a wireless telemetry device
Description: Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
Study: NCT02790164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmeron
Description: Neuromuscular Blockade

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal Saline
Study: NCT05921565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventional Behavioral Arm
Description: All participants will receive a weight loss intervention that includes 8 coaching sessions guided by a workbook they will at their baseline visit. During these sessions, they will meet with a health coach individually for up to 10-15 minutes via telephone or video conference to learn and discuss weight loss strategies. Health coaches will provide feedback and instruction (by phone or email) based on progress and challenges encountered during the intervention. Participants will receive a weight management app custom-built for the research study. The app will display participants' dietary intake, physical activity, and weight data and goals on the smartphone, and participants will use the app to log dietary intake, physical activity, and weight daily.
Study: NCT02376179

Intervention type: DEVICE
Intervention: Cuffed ETT
Study: NCT03917095

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Colonic Transendoscopic enteral Tubing.
Description: The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Colonic Transendoscopic enteral Tubing.
Description: The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Colonic Transendoscopic enteral Tubing.
Description: The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: The medications were infused into the colon
Study: NCT03657641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT03917095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: The medications were infused into the colon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: The medications were infused into the colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: The medications were infused into the colon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: The medications were infused into the colon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: The medications were infused into the colon
Study: NCT01564147

Intervention type: OTHER
Group type: OTHER
Intervention: immediate therapeutic education
Description: Access to the course of immediate therapeutic education

Intervention type: OTHER
Group type: OTHER
Intervention: therapeutic education delayed
Description: Group receiving therapeutic education 6 months later (control group)
Study: NCT00771966

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy
Description: Standard therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maximization of cardiac stroke volume with fluid infusion
Description: Maximization of cardiac stroke volume with fluid infusion
Study: NCT03753256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transbond XT
Description: Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protecto®CaF2Nano
Description: Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pro Seal®
Description: Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants.
Study: NCT03965741

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Follow clinical administration
Study: NCT03753256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opal®Seal
Description: Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants.